Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs
Methicillin-resistant Staphylococcus aureus (MRSA) pose a significant health threat as they
tend to cause severe infections in vulnerable populations and are difficult to treat due to a …
tend to cause severe infections in vulnerable populations and are difficult to treat due to a …
Novel antibiotics for multidrug-resistant gram-positive microorganisms
D Koulenti, E Xu, I Yin Sum Mok, A Song… - Microorganisms, 2019 - mdpi.com
Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci,
enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality …
enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality …
Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis
Abstract Background Methicillin-resistant Staphylococcus aureus (MRSA) infections are
considered an important public health problem, and treatment options are limited …
considered an important public health problem, and treatment options are limited …
A comprehensive overview of the antibiotics approved in the last two decades: retrospects and prospects
Z Shi, J Zhang, L Tian, L Xin, C Liang, X Ren, M Li - Molecules, 2023 - mdpi.com
Due to the overuse of antibiotics, bacterial resistance has markedly increased to become a
global problem and a major threat to human health. Fortunately, in recent years, various new …
global problem and a major threat to human health. Fortunately, in recent years, various new …
Common and rare hematological manifestations and adverse drug events during treatment of active TB: a state of art
ML Minardi, I Fato, F Di Gennaro, S Mosti… - Microorganisms, 2021 - mdpi.com
Background: Tuberculosis (TB) can seriously affect the hematopoietic system, with
involvement of both myeloid and lymphoid cell lines as well as plasma components. These …
involvement of both myeloid and lymphoid cell lines as well as plasma components. These …
A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
H Yang, Y Jin, H Wang, H Yuan, J Wang… - Antimicrobial Agents …, 2023 - Am Soc Microbiol
Contezolid acefosamil (also known as MRX-4), a prodrug of contezolid, is under
development for treatment of multidrug-resistant Gram-positive bacterial infections. A phase I …
development for treatment of multidrug-resistant Gram-positive bacterial infections. A phase I …
Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria
SS Jean, IM Liu, PC Hsieh, DH Kuo, YL Liu… - International Journal of …, 2023 - Elsevier
The infections caused by multidrug-and extensively drug-resistant (MDR, XDR) bacteria,
including Gram-positive cocci (GPC, including methicillin-resistant Staphylococcus aureus …
including Gram-positive cocci (GPC, including methicillin-resistant Staphylococcus aureus …
In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance …
S Wang, C Cai, Y Shen, C Sun, Q Shi, N Wu… - Frontiers in …, 2021 - frontiersin.org
Contezolid is a novel oxazolidinone, which exhibits potent activity against gram-positive
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin …
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin …
Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
B Li, Y Liu, J Luo, Y Cai, M Chen, T Wang - Frontiers in Pharmacology, 2023 - frontiersin.org
One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their
characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if …
characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if …
Nontuberculous mycobacteria in cystic fibrosis
CJ Richards, KN Olivier - Seminars in Respiratory and Critical …, 2019 - thieme-connect.com
Over the past decade, the incidence of nontuberculous mycobacterial (NTM) infection has
been increasing in cystic fibrosis patients. Along with this have come a host of complications …
been increasing in cystic fibrosis patients. Along with this have come a host of complications …